

INTERNATIONAL SYMPOSIUM ON:

Resolving Cancer Heterogeneity:

The way to personalised medicine

Palazzo della Gran Guardia Verona (Italy), June 30th – July 2nd, 2016





Centro di RICERCA APPLICATA ARC-NET

Organized by:

ARC-Net Centre for Applied Research on Cancer University of Verona (Italy)

Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston (Texas, USA)

- Welcome Letter from Congress & Scientific Chairs -

On behalf of the organizing committee, we are very pleased to welcome you to the International Symposium: "Resolving Cancer Heterogeneity: The way to personalised medicine" promoted by Fondazione Internazionale Menarini.

This unique meeting brings together leaders in the fields of translational clinical oncology and molecular pathology, in the beautiful and intimate setting of Palazzo dell Gran Guardia, right in the center of Verona.

Molecular characterization of cancer is becoming a necessary step for the application of precision medicine in clinical practice. Cancer heterogeneity represents a great challenge in our understanding of genomic tumor drivers and therapeutic targets

The goal of this symposium is to promote stimulating discussions and networking opportunities as we all strive to optimize our approaches for overcoming diagnostic challenges within the context of blood and tissue biopsies.

We hope that you will enjoy the exciting scientific program and take the opportunity to establish new contacts and collaborations that will foster your own work.

Alolo people 1. u. Inde

Kind Regards,

Prof. Aldo Scarpa Prof. Ignacio I. Wistuba

Co-Presidents of the Symposium

- Aldo Scarpa -

Department of Pathology and Diagnostics ARC-Net Centre for Applied Research on Cancer University of Verona (Italy)

- Ignacio I. Wistuba -

Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston (Texas, USA)

Promoted by

Fondazione Internazionale Menarini

Centro Direzionale Milanofiori

Edificio L - Strada 6 | 20089 Rozzano (Milan, Italy)

Phone: +39 02 55308110 - Fax: +39 02 55305739

milan@fondazione-menarini.it - www.fondazione-menarini.it

Organizing Secretariat

DueCi Promotion srl

Via C. Farini, 28 - 40124 Bologna (Italy)

Phone: +39 051 4841310 - Fax: +39 051 247165

ggrillenzoni@duecipromotion.com - www.duecipromotion.com

Under the auspicies of





- Program -

Thursday, June 30th, 2016 - Afternoon

- Opening ceremony

WELCOME ADDRESSES
06:00 p.m. Aldo Scarpa (Verona

Aldo Scarpa (Verona, I) and Ignacio I. Wistuba (Houston, USA)

Co-Presidents

06:15 p.m. Anirban Maitra (Houston, USA)

Emerging targets from the pancreatic cancer genome

07:00 p.m. Welcome cocktail

Friday, July 1st, 2016 - Morning

Session I

-Treatment decision-making in solid tumors: the unaddressed needs

Chairperson:	Filippo de Braud (Milan, I)
08:30 a.m.	Dario Marchetti (Houston, USA) Dissecting CTC subsets: insights into the evolution of breast cancer CTCs mediating brain metastasis
09:00 a.m.	Daniela Cesselli (Udine, I) Identification of circulating tumor cells in epithelial-to-mesenchymal transition in metastatic breast cancer patients
09:30 a.m.	Anna Sapino (Torino, I) Assessing tumor beterogeneity in breast cancer
10:00 a.m.	Pierfranco Conte (Padua, I) Change of molecular characteristic and breast cancer progression
10:30 a.m.	Coffee break
11:00 a.m.	Nikolas Stoecklein (Dusseldorf, D) Genomic profiling of HNSCC on the single cell level indicates metastasis-relevant genes
11:30 a.m.	Giorgio Stanta (Trieste, I) Functional and not clonal beterogeneity: practical approaches
12:00 p.m.	Klaus Pantel (Hamburg, D) Liquid biopsy: implications for cancer therapy
12:30 p.m.	Discussion
01:00 p.m.	Lunch

- Intra and inter-tumor heterogeneity: current issues and treatment efficacy

Chairperson:	Aldo Scarpa (Verona, I)
02:00 p.m.	Paola Gazzaniga (Rome, I) Molecular features of circulating tumor cells in lung cancer patients treated with checkpoint inhibitors: avoiding predation
02:30 p.m.	Justo P. Castaño Fuentes (Còrdoba, E) Splicing defects as a novel factor contributing to tumor development and beterogeneity
03:00 p.m.	Peter Metrakos (Montreal, CDN) Heterogeneity in colorectal cancer metastasis and response to therapy
03:30 p.m.	Matija Snuderl (New York, USA) Dissecting epigenetic beterogeneity in cancer: functional implications and therapeutic opportunities
04:00 p.m.	Coffee break
04:30 p.m.	Tatsuhiro Shibata (Tokio, J) Liver cancer beterogeneity
05:00 p.m.	Samra Turajlic (London, UK) Mapping renal cancer evolution through space and time
05:30 p.m.	Pamela Pinzani (Florence, I) Mutational analysis of single circulating tumor cells
06:00 p.m.	Discussion

- Limitations of tumor biopsy & technology solutions

Chairperson:	Ignacio I. Wistuba (Houston, USA)
08.30 a.m.	Catherine Alix-Panabieres (Montpelliér, F) Detection, characterization and ex vivo expansion of viable circulating tumor cells
09.00 a.m.	Rafael Rosell (Barcellona, E) Future perspectives for treatment strategies in EGFR mutant NSCLC
09.30 a.m.	Giampaolo Tortora (Verona, I) Clinical translation of biomolecular studies in pancreas cancer patients
10.00 a.m.	Zofia Piotrowska (Boston, USA) Heterogeneity of resistance mechanisms in EGFR-mutant NSCLC
10.30 a.m.	Coffee break
11.00 a.m.	Bin Tean Teh (Singapore, SGP) Asian Cancer Genomics and Its Clinical Implications
11.30 a.m.	Jianjun Zhang (Houston, USA) The potential impact of intra-tumor beterogeneity on biopsy and molecular profiling in lung cancer
12.00 p.m.	Johann de Bono (London, UK) Molecular predictive biomarkers for target agents in prostate cancer
12.30 p.m.	Aldo Scarpa (Verona, I) Identification of potentially druggable pathways in solid cancers by molecular profiling via next generation sequencing
01.00 p.m.	Discussion
01.30 p.m.	Lunch

- Faculty -

- ALIX-PANABIERES CATHERINE

Laboratoire Cellules Circulantes Rares Humaines
Department of Cell and Tissue Biopathology of Tumors
University Medical Center
Montpellier, France

CASTAÑO FUENTES JUSTO P.

Institute for Biomedical Research Maimónides of Córdoba Reina Sofía University Hospital and University of Córdoba, Spain

- CESSELLI DANIELA

Department of Medical and Biological Sciences University of Udine, Italy

CONTE PIERFRANCO

Division of Medical Oncology Department of Surgical Oncology and Gastroenterological University of Padua, Italy

DE BONO JOHANN

The Institute of Cancer Research The Royal Marsden NHS Foundation Trust London, United Kingdom

- DE BRAUD FILIPPO

Department and Division of Medical Oncology 1 Fondazione IRCCS Istituto Nazionale Tumori University of Milan, Italy

GAZZANIGA PAOLA

Department of Molecular Medicine University of Rome La Sapienza Rome, Italy

- MAITRA ANIRBAN

Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research The University of Texas Anderson Cancer Center Houston, United States of America

- MARCHETTI DARIO

Houston Methodist Research Institute Department of Pathology and Genomic Medicine Methodist Hospital Houston, United States of America

METRAKOS PETER

Department of Surgery Section of Transplantation and Hepatopancreatobiliary Surgery McGill University Health Centre Cancer Research Program Montreal, Canada

- PANTEL KLAUS

Department of Tumor Biology University Medical Center Hamburg-Eppendorf Center of Experimental Medicine Hamburg, Germany

- PINZANI PAMELA

Department of Experimental Clinical and Biomedical Sciences University of Florence, Italy

- PIOTROWSKA ZOFIA

Center for Thoracic Cancers Massachusetts General Hospital Cancer Center Boston, United States of America

- Faculty -

- ROSELL RAFAEL

Catalan Institute of Oncology Germans Trias i Pujol Health Sciences Institute and Hospital Campus Can Ruti Badalona, Barcelona, Spain

- SAPINO ANNA

Service of Surgical Pathology Fondazione del Piemonte per l'Oncologia IRCC Candiolo Department of Medical Sciences University of Turin, Italy

- SCARPA ALDO

Department of Pathology and Diagnostics ARC-Net Centre for Applied Research on Cancer University of Verona, Italy

- SHIBATA TATSUHIRO

Laboratory of Molecular Medicine Human Genome Center The Institute of Medical Science The University of Tokyo Division of Cancer Genomics National Cancer Center Tokyo, Japan

- SNUDERL MATIJA

Department of Pathology New York University School of Medicine New York, United States of America

- STANTA GIORGIO

Department of Medical Sciences University of Trieste, Italy

STOECKLEIN NIKOLAS

Experimental Surgical Oncology Department for General, Visceral and Pediatric Surgery University Hospital of Düsseldorf, Germany

- TEH BIN TEAN

National Cancer Centre Singapore SingHealth Duke-NUS Institute of Precision Medicine Duke-NUS Medical School Institute of Molecular and Cell Biology Cancer Science Institute of Singapore, Singapore

- TORTORA GIAMPAOLO

Division of Medical Oncology Faculty of Medicine and Surgery University of Verona, Italy

- TURAJLIC SAMRA

The Francis Crick Institute and The Royal Marsden Hospital London, United Kingdom

- WISTUBA IGNACIO I.

Department of Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston, United States of America

- ZHANG JIANJUN

Department of Thoracic/Head and Neck Medical Oncology Department of Genomic Medicine Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, United States of America

- General Information -

Meeting venue

The venue for the symposium is Palazzo della Gran Guardia | Piazza Bra, 1 - Verona

Official language

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration includes

Access to scientific sessions, welcome cocktail, coffee breaks, lunch, program book, certificate of attendance.

